Zehan Chen

发表

Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors.

Saul H. Rosenberg, Chang Park, P. Kovar, 2006, Bioorganic & medicinal chemistry letters.

Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

Zhan Xiao, John Xue, Saul H Rosenberg, 2006, International journal of cancer.

Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

Saul H Rosenberg, Philip J. Merta, Gaoquan Li, 2007, Bioorganic & medicinal chemistry letters.

NMR structure and mutagenesis of the FADD (Mort1) death-effector domain

Stephen W. Fesik, R. Meadows, S. Fesik, 1998, Nature.

Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1

Hua Tang, Mark E Schurdak, Michael Coen, 2006, Journal of biomolecular screening.

Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

Chang Park, Philip J. Merta, Z. Tao, 2007, Journal of medicinal chemistry.

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.

Chang Park, Saul H Rosenberg, Gaoquan Li, 2006, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

Chang Park, John Xue, Saul H Rosenberg, 2007, Journal of medicinal chemistry.

Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.

Chang Park, Saul H Rosenberg, Y. Tong, 2007, Bioorganic & medicinal chemistry.